Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — ShareCafe Small Cap "Hidden Gems" Webinar (December 2022)
13 slides from Genetic Signatures's conference presentation, Dec 9, 2022
Slide 1: Investor Webinar Presentation (ASX announcement)
ASX announcement 9 December 2022 INVESTOR WEBINAR PRESENTATION For personal use only Genetic Signatures Limited (ASX: GSS) is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 9th of December 2022 from 12:30pm AEDT/ 9:30am AWST. John Melki - CE
Slide 2: Investor Presentation December 2022
For personal use only Investor Presentation December 2022
Slide 3: Disclaimer
DOCUMENT ShareTITLE Cafe Disclaimer December October 2021 2022 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written For personal use only materials/slides for a verbal presentat
Slide 4: Investment highlights
Investment highlights DOCUMENT ShareTITLE December Cafe October 2021 2022 Proprietary 3base® technology platform - a revolutionary approach For personal use only for molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiplexing); more informative, Simpler
Slide 5: Company Snapshot
DOCUMENT ShareTITLE Cafe Company Snapshot December October 2021 2022 For personal use only Financial information Share price Volume (m) 2.00 (A$) 4.00 Share price (8-Dec-22) A$0.80 1.80 3.50 Shares on issue 143.4m 1.60 3.00 1.40 2.50 Market capitalisation A$114.7m 1.20 1.00 2.00 0.80 Cash (30-Sep-22
Slide 6: Track record of continued, strong revenue growth
Track record of continued, strong revenue growth DOCUMENT ShareTITLE December Cafe October 2021 2022 Sales Revenue (A$m) Q1 FY23 sales up 16% from preceding quarter For personal use only • FY22 sales revenue of $35.4 million (+25% yoy, 89% 4yr CAGR) Growing contribution from international sales 35.4
Slide 7: How 3base simplifies molecular targets
DOCUMENT ShareTITLE Cafe How 3base® simplifies molecular targets December October 2021 2022 For personal use only Molecular diagnostic tests are based on DNA/RNA sequences • DNA/RNA is unique to each organism. Genetic Signatures 3base® makes multiplex testing easier: • More informative – detect rela
Slide 8: 3base simplifies Syndromic Testing – EasyScreen Kits
3base® simplifies Syndromic Testing – EasyScreen™ Kits DOCUMENT TITLE Share Cafe October2022 December 2021 For personal use only Syndromic testing: simultaneously test for multiple pathogens that all can cause the same signs and symptoms • Respiratory infections: cough, runny nose, sore throat, head
Slide 9: Robust pipeline with multiple products cleared for sale
Robust pipeline with multiple products cleared for sale DOCUMENT ShareTITLE December Cafe October 2021 2022 For personal use only DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 8
Slide 10: Enteric Protozoan kit will provide entry to North America
Enteric Protozoan kit will provide entry to North America DOCUMENT TITLE Share Cafe October2022 December 2021 High need for Enteric Protozoan Kit For personal use only • 5.5 million tests conducted in the US pa; • Primarily culture/microscopy: slow, labour intensive, unreliable; • Detects leading pr
Slide 11: Growth initiatives
Growth initiatives DOCUMENT ShareTITLE December Cafe October 2021 2022 Leverage experience in AU market to grow international sales For personal use only • Europe – drive adoption of other 3base® products; • US – build 3base® franchise once Protozoan Detection Kit is cleared. Build & expand portfoli
Slide 12: Upcoming milestones
Upcoming milestones – 12 months DOCUMENT ShareTITLE December Cafe October 2021 2022 For personal use only US Enteric Protozoan Kit • File 510(k) application 1Q CY23; • Launch product once clearance is granted. Increase sales and presence in UK and European markets • Contracts with new customers; • D
Slide 13: Contact Us
For personal use only Contact Us Dr John Melki Genetic Signatures Ltd Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us www.geneticsignatures.com Follow us 12
Genetic Signatures — ShareCafe Small Cap "Hidden Gems" Webinar (December 2022) on 6ix